Zollinger-Ellison Syndrome
3
Pipeline Programs
2
Companies
2
Clinical Trials
2
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
2
Early DiscoveryClinical DevelopmentMarket
On Market (2)
Approved therapies currently available
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
AstraZenecaEsomeprazole magnesium
Trio MedicinesYF476
Clinical Trials (2)
Total enrollment: 28 patients across 2 trials
Esomeprazole In Patients With Gastric Acid Hypersecretory States Including Idiopathic Hypersecretion and Zollinger-Ellison Syndrome
Start: Nov 2003Est. completion: Jul 200525 patients
Phase 3Completed
YF476 and Type II Gastric Carcinoids
Start: Apr 2011Est. completion: Jun 20123 patients
Phase 2Terminated
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs, potential near-term approvals
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.